Print

Teva Pharmaceutical Industries Limited (TEVA) Announces Launch of Generic Actos® in the United States  
8/17/2012 9:35:43 AM

JERUSALEM--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today the launch of an authorized generic of Actos® (pioglitazone-hydrochloride tablets) 15, 30 and 45mg. Actos® is marketed by Takeda Pharmaceuticals U.S.A., Inc. and used with diet and exercise to improve blood sugar (glucose) control in adults with type 2 diabetes. The brand product had annual sales of approximately $2.7 billion in the United States, based on IMS sales data as of June 30, 2012.
//-->